Integrating Care After Exacerbation of COPD (InCasE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02021955|
Recruitment Status : Completed
First Posted : December 27, 2013
Last Update Posted : March 22, 2021
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Behavioral: guideline treatment recommendations||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||362 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Integrating Care After Exacerbation of COPD (InCasE)|
|Actual Study Start Date :||February 11, 2015|
|Actual Primary Completion Date :||November 29, 2018|
|Actual Study Completion Date :||January 31, 2019|
No Intervention: usual care
Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
Experimental: guideline treatment recommendations
Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
Behavioral: guideline treatment recommendations
Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
- hospital re-admission and mortality [ Time Frame: 180 days post-discharge ]Composite measure of hospital readmission for any cause at 180 days and all-cause mortality.
- COPD-related patient quality-of-life (Clinical COPD Questionnaire) [ Time Frame: 6 weeks post-discharge ]self-report survey of patients' quality-of-life
- General health status (Veterans RAND 12 Item Health Survey ) [ Time Frame: 6 weeks post-discharge ]self-report survey of patients' general health quality-of-life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02021955
|United States, Idaho|
|Boise VA Medical Center, Boise, ID|
|Boise, Idaho, United States, 83702|
|United States, Washington|
|VA Puget Sound Health Care System Seattle Division, Seattle, WA|
|Seattle, Washington, United States, 98108|
|Principal Investigator:||David H. Au, MD MS||VA Puget Sound Health Care System Seattle Division, Seattle, WA|